AI-Powered Breast Cancer Screening Solution for Healthcare Providers
Thermalytix® is Niramai’s patented, AI-based breast cancer screening solution designed to assist healthcare providers in the early detection of breast abnormalities. The procedure is contactless, radiation-free, and painless — suitable for women of all age groups. Learn more here.
Regulatory Cleared
39 Patents Granted
Made in India
India
Europe, Africa & Asia
ISO 13485:2016 Certified
ISO 27001 Certified
USFDA for SMILE100
How Thermalytix® Can Enhance Breast Cancer Screening Services
Adjunct Tool for Breast Cancer Screening Complements Clinical Breast Examination, Mammography, and Ultrasound to broaden screening programs.
Ideal for Screening Women with Dense Breasts Provides valuable breast health support for dense tissue cases.
Portable and Easy to Deploy Suitable for hospitals, clinics, health camps, outreach programs, and mobile health units.
Seamless Integration with Preventive Health Packages Easily incorporated into checkups, master health plans, and corporate wellness programs.
Clinical Studies & Publications of Thermalytix
BMJ Open Multicentric study to evaluate the effectiveness of Thermalytix as compared with standard screening modalities in subjects who show possible symptoms of suspected breast cancer.View Publication
ASCO JCO Observational study on the clinical efficacy of Thermalytix for detecting breast cancer in symptomatic and asymptomatic women, published in the Journal of Clinical Oncology Global Oncology.View Publication
Frontiers in AI Journal Prospective evaluation of breast thermography enhanced by a novel machine learning technique for screening breast abnormalities in women at a secondary care hospital, published in Frontiers.View Publication
Int. J Community Medicine Feasibility and outcomes of using a novel artificial intelligence enhanced breast thermography technique, Thermalytix, in screening for breast abnormalities at primary health centres at the community level in South IndiaView Publication
Lancet Oncology Performance of artificial intelligence-based breast cancer screening in a community setting: a real-world evaluation study. The Lancet Oncology. 2022 Jul 1;23:S20View Publication
SABCS 2022 An Automated Risk Stratification System for Breast Cancer Screening using Thermalytix. Cancer Research. 2023 Mar 1;and San Antonio Breast Cancer Symposium Dec 2022:P3-03View Publication
Our Partners
What Our Clients Say
HCG Hospital
Onco Life
Navchetna